
Biotech Business - April 29, 2013
MedImmune acquires AlphaCorePharma
AstraZeneca’s global biologics R&D arm MedImmune has acquired AlphaCorePharma. The Michigan-based biotech company focuses on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. Cardiovascular and metabolic disease is a core therapy area for AstraZeneca’s small and large molecule research. “As the science in this area continues to evolve, we are committed to […]